Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;20(1):2348135.
doi: 10.1080/21645515.2024.2348135. Epub 2024 May 13.

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Narmeen Mallah  1   2   3   4 , Sonia Ares-Gómez  1   2   5 , Jacobo Pardo-Seco  1   2   5   6 , Alberto Malvar-Pintos  7 , María-Isolina Santiago-Pérez  7 , Olaia Pérez-Martínez  7 , María-Teresa Otero-Barrós  7 , Nuria Suárez-Gaiche  7 , Rolf Kramer  8 , Jing Jin  8 , Leticia Platero-Alonso  8 , Rosa-María Alvárez-Gil  9 , Olga-María Ces-Ozores  9 , Victoria Nartallo-Penas  9 , Susana Mirás-Carballal  9 , Marta Piñeiro-Sotelo  7 , Juan-Manuel González-Pérez  10 , Carmen Rodríguez-Tenreiro  1   2   5 , Irene Rivero-Calle  1   2   5   11 , Antonio Salas  1   5   6   12 , Carmen Durán-Parrondo  13 , Federico Martinón-Torres  1   2   5   11
Affiliations

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Narmeen Mallah et al. Hum Vaccin Immunother. .

Abstract

Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023. It aims to evaluate nirsevimab effectiveness against RSV-related hospitalizations lower respiratory tract infections (LRTI), severe RSV, all-cause LRTI, and all-cause hospitalization. NIRSE-GAL also aims to estimate nirsevimab impact on primary healthcare use in the short and mid-term, children's wheezing and asthma, and medical prescriptions for RSV. The immunization campaigns will be scheduled based on the expected start week for the RSV season and will last the whole season. Immunization will be offered to: i) infants born during the campaign (seasonal), ii) infants < 6 months at the start of the campaign (catch-up), and iii) infants with high-risk factors, aged 6-24 months at the start of the campaign (high-risk). The follow-up period will start: i) the immunization date for all immunized infants, ii) the start of the campaign, for the non-immunized catch-up or high-risk groups, or iii) the birthdate for the non-immunized seasonal group. Infants will be followed up until outcome occurrence, death, or end of study. Nirsevimab effectiveness will be estimated using Poisson and Cox regression models. Sensitivity and stratified analyses will be undertaken. The number of averted cases and the number needed to immunize will be estimated. Immunization failure and nirsevimab safety will be monitored. NIRSE-GAL was approved by the ethics committee of Galicia (CEIC 2023-377) and registered in ClinicalTrials.gov (ID: NCT06180993). Findings will be mainly shared via peer-reviewed publications and scientific conferences.

Keywords: Effectiveness; immunization; longitudinal population-based study; lower respiratory tract infection; nirsevimab; respiratory syncytial virus.

PubMed Disclaimer

Conflict of interest statement

Federico Martinón-Torres has acted as principal investigator in randomized controlled trials of Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis and GSK, with honoraria paid to his institution. Federico Martinon-Torres reports a relationship with GSK Vaccines SRL that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with Pfizer Inc that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with Sanofi Pasteur Inc that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with MSD that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with Seqirus Pty Ltd that includes: consulting or advisory. IRC has received speaking fees from MSD, GSK, Sanofi, Moderna and Pfizer. IRC has participated in advisory boards organized by MSD, GSK, Sanofi and Pfizer. IRC has been involved in clinical trials funded by Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis and GSK, although the funds were paid to her institution. Rolf Kramer, Jing Jin and Leticia Platero-Alonso are Sanofi employees and may hold shares and/or stock options in the company. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simões EAF, Campbell H. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–10. doi:10.1016/S0140-6736(22)00478-0. - DOI - PMC - PubMed
    1. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–9. doi:10.1056/NEJMoa1211917. - DOI - PubMed
    1. Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J. 2003;22(2 Suppl):S6–10. discussion S-2. doi:10.1097/01.inf.0000053880.92496.db. - DOI - PubMed
    1. Viguria N, Martinez-Baz I, Moreno-Galarraga L, Sierrasesumaga L, Salcedo B, Castilla J, Morrow BM. Respiratory syncytial virus hospitalization in children in northern Spain. PLoS One. 2018;13(11):e0206474. doi:10.1371/journal.pone.0206474. - DOI - PMC - PubMed
    1. Demont C, Petrica N, Bardoulat I, Duret S, Watier L, Chosidow A, Lorrot M, Kieffer A, Lemaitre M. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis. 2021;21(1):730. doi:10.1186/s12879-021-06399-8. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data